ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis

Angiogenesis

Volumn 18, Issue 1, 2015, Pages 13-22

  Caolo, V ^a   Swennen, G ^a   Chalaris, A ^c   Wagenaar, A ^a   Verbruggen, S ^a   Rose John, S ^c   Molin, D G M ^a   Vooijs, M ^b   Post, M J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

ADAMs; Angiogenesis; Notch; Tumour

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE 17; ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; GAMMA SECRETASE; NOTCH RECEPTOR; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; ADAM10 PROTEIN, MOUSE; COLLAGEN; DLL4 PROTEIN, MOUSE; DRUG COMBINATION; LAMININ; MATRIGEL; MEMBRANE PROTEIN; PRIMER DNA; PROTEOGLYCAN; SECRETASE; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; SIGNAL TRANSDUCTION; ANALYSIS OF VARIANCE; ANIMAL; DRUG COMBINATION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; COLLAGEN; DNA PRIMERS; DRUG COMBINATIONS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LAMININ; MEMBRANE PROTEINS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEOGLYCANS; RECEPTORS, NOTCH; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1;

EID: 84920097040     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-014-9443-4     Document Type: Article

References (26)

1. Glomski K, Monette S, Manova K, De Strooper B, Saftig P, Blobel CP (2011) Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures. Blood 118(4):1163–1174
2. Donners MM, Wolfs IM, Olieslagers S, Mohammadi-Motahhari Z, Tchaikovski V, Heeneman S, van Buul JD, Caolo V, Molin DG, Post MJ, Waltenberger J (2010) A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis. Arterioscler Thromb Vasc Biol 30(11):2188–2195
3. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, Hinoki A, Eguchi S, Guaiquil V, Horiuchi K, Blobel CP (2010) Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res 106(5):932–940
4. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445(7129):776–780
5. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA (1998) An essential role for ectodomain shedding in mammalian development. Science 282(5392):1281–1284
6. van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M (2009) Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 284(45):31018–31027
7. Groot AJ, Cobzaru C, Weber S, Saftig P, Blobel CP, Kopan R, Vooijs M, Franzke CW (2013) Epidermal ADAM17 is dispensable for Notch activation. J Invest Dermatol 133(9):2286
8. Manilay JO, Anderson AC, Kang C, Robey EA (2005) Impairment of thymocyte development by dominant-negative Kuzbanian (ADAM-10) is rescued by the Notch ligand, delta-1. J Immunol 174(11):6732–6741
9. Weber S, Niessen MT, Prox J, Lullmann-Rauch R, Schmitz A, Schwanbeck R, Blobel CP, Jorissen E, de Strooper B, Niessen CM, Saftig P (2011) The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development 138(3):495–505
10. Bozkulak EC, Weinmaster G (2009) Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 29(21):5679–5695
11. Sulis ML, Saftig P, Ferrando AA (2011) Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. Leukemia 25(10):1564–1569
12. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, Jostock T, Matthews V, Hasler R, Becker C, Neurath MF, Reiss K, Saftig P, Scheller J, Rose-John S (2010) Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 207(8):1617–1624
13. Williams CK, Li JL, Murga M, Harris AL, Tosato G (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107(3):931–939
14. Lemieux GA, Blumenkron F, Yeung N, Zhou P, Williams J, Grammer AC, Petrovich R, Lipsky PE, Moss ML, Werb Z (2007) The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. J Biol Chem 282(20):14836–14844
15. van den Akker NM, Caolo V, Wisse LJ, Peters PP, Poelmann RE, Carmeliet P, Molin DG, Gittenberger-de Groot AC (2008) Developmental coronary maturation is disturbed by aberrant cardiac vascular endothelial growth factor expression and notch signalling. Cardiovasc Res 78(2):366–375
16. Sawamiphak S, Ritter M, Acker-Palmer A (2010) Preparation of retinal explant cultures to study ex vivo tip endothelial cell responses. Nat Protoc 5(10):1659–1665
17. Lucitti JL, Jones EA, Huang C, Chen J, Fraser SE, Dickinson ME (2007) Vascular remodeling of the mouse yolk sac requires hemodynamic force. Development 134(18):3317–3326
18. Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, Swerlick R, Bornstein P, Lawler J, Benjamin LE (2009) Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol 296(5):H1344–H1351. doi:10.1152/ajpheart.01246.2008
19. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D, Bissell MJ (2013) The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15(7):807–817
20. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD (2004) Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA 101(45):15949–15954
21. Hainaud P, Contreres JO, Villemain A, Liu LX, Plouet J, Tobelem G, Dupuy E (2006) The role of the vascular endothelial growth factor-delta-like 4 ligand/notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 66(17):8501–8510
22. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65(19):8690–8697
23. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G (2007) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found Symp 283:106–120; discussion 121–105, 238–141
24. Thurston G, Noguera-Troise I, Yancopoulos GD (2007) The Delta paradox: dLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7(5):327–331
25. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463(7282):E6–E7
26. Das S, Czarnek M, Bzowska M, Mezyk-Kopec R, Stalinska K, Wyroba B, Sroka J, Jucha J, Deneka D, Stoklosa P, Ogonek J, Swartz MA, Madeja Z, Bereta J (2012) ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One 7(12):e50791